Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE

Lysophosphatidylcholine (LPC) is present in oxidized low density lipoprotein (oxLDL), which is implicated in atherosclerosis. Antibodies to cardiolipin (aCL) and oxLDL (aoxLDL) have been shown to crossreact. LPC is formed by hydrolysis of phosphatidylcholine (PC) in LDL and cell membranes, induced by phospholipase A2 or by oxidation. We here demonstrate the presence of enhanced antibody levels to LPC in 184 patients with SLE as compared to 85 healthy, age-matched controls. The antibody reactivity to LPC was not specifically related to oxidation of the fatty acid moiety in LPC, since LPC containing only the saturated fatty acid palmitic acid showed equivalent antibody levels as LPC containing unsaturated fatty acids. aPC were significantly lower as compared to aLPC, indicating that hydrolysis of PC at the sn-2 position increases the antigenic potential of the molecule. β-glycoprotein 1 was a cofactor for aCL, but not for aoxLDL or aLPC, and the antigenicity of these compounds is therefore not directly related to β2GP1. There was a close correlation between aoxLDL, aCL and aLPC and both LPC and oxLDL competitively inhibited aCL-binding to CL. LPC, oxLDL and CL thus display a common antigenic site, which could be formed by removal of a fatty acid at the sn-2 position, possibly due to the activity to phospholipase A2 and/or oxidation. This study indicates the potential role of LDL-oxidation and phospholipase A2 in SLE.

[1]  L. Elinder,et al.  Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[2]  U. Hedin,et al.  Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[3]  J. Witztum,et al.  The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[5]  J. Smolen,et al.  Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. , 1996, British journal of rheumatology.

[6]  Pojen P. Chen,et al.  A monoclonal IgG anticardiolipin antibody from a patient with the antiphospholipid syndrome is thrombogenic in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R. Terkeltaub,et al.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. , 1996, The Journal of clinical investigation.

[8]  Y. Shoenfeld,et al.  Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. , 1996, Circulation.

[9]  U. Faire,et al.  Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease , 1995, Journal of internal medicine.

[10]  J. Frostegård,et al.  Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A. Lefvert,et al.  Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL , 1995, Clinical and experimental immunology.

[12]  G. Hughes,et al.  Antiphospholipid antibodies and antiphospholipid syndrome , 1995, Current opinion in rheumatology.

[13]  Ming Liu,et al.  Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Alarcón-Segovia,et al.  Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[15]  D. Steinberg,et al.  Recognition of oxidatively damaged erythrocytes by a macrophage receptor with specificity for oxidized low density lipoprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Gladman,et al.  Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. , 1994, The Journal of rheumatology.

[17]  M. Jauhiainen,et al.  Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus , 1993, The Lancet.

[18]  M. Stampfer,et al.  Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis , 1992, Annals of Internal Medicine.

[19]  M. Petri,et al.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.

[20]  O. Nived,et al.  Cardiovascular Disease in Systemic Lupus Erythematosus A Study of 75 Patients from a Defined Population , 1992, Medicine.

[21]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[22]  R. Giscombe,et al.  Induction of T-cell activation by oxidized low density lipoprotein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  D. Gladman,et al.  Peripheral vascular disease in patients with systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.

[24]  D. Gladman.  Prognosis of systemic lupus erythematosus and factors that affect it , 1991, Current opinion in rheumatology.

[25]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Hamsten,et al.  Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Steinberg.  Book ReviewAmbulatory Pediatric Care , 1989 .

[28]  C. Bombardier,et al.  Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. , 1988, The Journal of rheumatology.

[29]  D. Steinberg,et al.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Hughes,et al.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. , 1987, Clinical and experimental immunology.

[31]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[32]  W. Roberts,et al.  Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. , 1981, The American journal of medicine.

[33]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[34]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[35]  S. Shapiro,et al.  The lupus anticoagulant/antiphospholipid syndrome. , 1996, Annual review of medicine.

[36]  S. Abramson,et al.  Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. , 1996, Arthritis and rheumatism.

[37]  P. Vadas,et al.  Phospholipase A2--a mediator between proximal and distal effectors of inflammation. , 1991, Immunology today.

[38]  T. Carew,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.